Posted On: 06/24/2014 9:21:43 PM
Post# of 30070
don't forget this one regarding MANF RP
Amarantus Bioscience Holdings, Inc. Obtains Exclusive Option to License University of Miami Bascom Palmer Eye Institute's Intellectual Property for the Treatment of Retinal Diseases Using MANF and CDNF
http://investing.businessweek.com/research/st...d=20801521
Dec. 3, 2013
Amarantus Bioscience Holdings Inc. announced that it has entered into an exclusive option agreement with the University of Miami to license the Bascom Palmer Eye Institute's method of use intellectual property surrounding the use of MANF and CDNF for the treatment of retinal diseases. The option agreement includes all intellectual property covering the use of the MANF-Family of proteins (MANF and CDNF) for retinal diseases including age-related macular degeneration, glaucoma, inherited retinal disorders (including Retinitis Pigmentosa), sporadic retinal disorders, other degenerative retinal disorders, and retinal injuries. This option agreement follows previously announced positive data for MANF in the S334ter Type 3 genetic mouse model of Retinitis Pigmentosa. The company owns composition of matter patents and various composition and method of use patent applications for MANF and derivative sequences for protein therapeutic, gene therapy and certain cell therapy applications.
Amarantus Bioscience Holdings, Inc. Obtains Exclusive Option to License University of Miami Bascom Palmer Eye Institute's Intellectual Property for the Treatment of Retinal Diseases Using MANF and CDNF
http://investing.businessweek.com/research/st...d=20801521
Dec. 3, 2013
Amarantus Bioscience Holdings Inc. announced that it has entered into an exclusive option agreement with the University of Miami to license the Bascom Palmer Eye Institute's method of use intellectual property surrounding the use of MANF and CDNF for the treatment of retinal diseases. The option agreement includes all intellectual property covering the use of the MANF-Family of proteins (MANF and CDNF) for retinal diseases including age-related macular degeneration, glaucoma, inherited retinal disorders (including Retinitis Pigmentosa), sporadic retinal disorders, other degenerative retinal disorders, and retinal injuries. This option agreement follows previously announced positive data for MANF in the S334ter Type 3 genetic mouse model of Retinitis Pigmentosa. The company owns composition of matter patents and various composition and method of use patent applications for MANF and derivative sequences for protein therapeutic, gene therapy and certain cell therapy applications.
(0)
(0)
